Contineum Therapeutics (CTNM) Stifel 2025 Virtual CNS Forum summary

Company overview and pipeline focus

• Focuses on neuroscience, inflammation, and immunology, with all assets internally developed and initially targeted for neuroscience indications.

• Seven clinical studies planned for 2025, including four for lead asset 791, two for PIPE-307 (partnered with J&J), and a novel program entering healthy volunteer studies.

• Portfolio benefits from clinical validation in three disease areas, supported by pharma and academic data, reducing risk.

• Some programs are preclinically validated, offering white space opportunities for future development.

PIPE-307: Remyelination and depression programs

• PIPE-307 is a selective M1 receptor antagonist, aiming to promote remyelination in MS by advancing oligodendrocyte differentiation.

• The VISTA phase II study for relapsing-remitting MS is fully enrolled, with top-line data expected in the second half of the year.

• The study uses functional biomarkers like VEP latency and low-contrast letter acuity to demonstrate remyelination within a 6-month timeframe.

• In depression, M1 antagonism is supported by rapid, robust clinical responses to scopolamine, with a 124-patient phase IIB study (Moonlight One) underway by J&J.

• Safety data from healthy volunteers and patients show no cognitive issues, supporting the selective M1 antagonist approach.

LPA1 program: Progressive MS, IPF, and pain

• LPA1 is targeted for inflammatory demyelination, with preclinical data showing that blocking LPA1 reduces neuroinflammation and promotes remyelination.

• EAE models confirm efficacy in remyelination and neuroinflammation, bridging preclinical and clinical relevance.

• Upcoming phase IIa study in progressive MS will focus on imaging biomarkers (MRI, myelin water fraction, MTR, MTI) and neuroinflammation metrics, with study start anticipated in the second half of the year.

• PET studies are ongoing to optimize dosing for both progressive MS and idiopathic pulmonary fibrosis, with data expected next quarter.

• LPA1 pathway is also being explored for neuropathic pain, supported by academic and non-human primate data.